120 related articles for article (PubMed ID: 8537156)
1. Plasminogen activators, venous leg ulcers and reepithelialization.
Lotti T; Benci M
Int J Dermatol; 1995 Oct; 34(10):696-9. PubMed ID: 8537156
[TBL] [Abstract][Full Text] [Related]
2. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
3. Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Stacey MC; Burnand KG; Mahmoud-Alexandroni M; Gaffney PJ; Bhogal BS
Br J Surg; 1993 May; 80(5):596-9. PubMed ID: 8518896
[TBL] [Abstract][Full Text] [Related]
4. Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
Rogers AA; Burnett S; Lindholm C; Bjellerup M; Christensen OB; Zederfeldt B; Peschen M; Chen WY
Vasa; 1999 May; 28(2):101-5. PubMed ID: 10409920
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activation in venous leg ulcers.
Herouy Y; Trefzer D; Hellstern MO; Stark GB; Vanscheidt W; Schöpf E; Norgauer J
Br J Dermatol; 2000 Nov; 143(5):930-6. PubMed ID: 11069499
[TBL] [Abstract][Full Text] [Related]
6. Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.
Lagattolla NR; Stacey MC; Burnand KG; Gaffney PG
Ann Cardiol Angeiol (Paris); 1995; 44(6):299-303. PubMed ID: 7574362
[TBL] [Abstract][Full Text] [Related]
7. Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency.
Peschen M; Rogers AA; Chen WY; Vanscheidt W
Acta Derm Venereol; 2000 May; 80(3):162-6. PubMed ID: 10954203
[TBL] [Abstract][Full Text] [Related]
8. Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing.
Wysocki AB; Kusakabe AO; Chang S; Tuan TL
Wound Repair Regen; 1999; 7(3):154-65. PubMed ID: 10417751
[TBL] [Abstract][Full Text] [Related]
9. Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor.
Kolbach DN; Hamulyák K; Prins MH; Neumann HA; Cleutjens JP
Vasa; 2004 Feb; 33(1):19-24. PubMed ID: 15061043
[TBL] [Abstract][Full Text] [Related]
10. Lower levels of PAI-2 may contribute to impaired healing in venous ulcers - a preliminary study.
Stacey MC; Mata SD
Cardiovasc Surg; 2000 Aug; 8(5):381-5. PubMed ID: 10959063
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activation in healing human wounds.
Schäfer BM; Maier K; Eickhoff U; Todd RF; Kramer MD
Am J Pathol; 1994 Jun; 144(6):1269-80. PubMed ID: 8203466
[TBL] [Abstract][Full Text] [Related]
12. Keratinocyte and dermal vascular endothelial cell capacities remain unimpaired in the margin of chronic venous ulcer.
Galkowska H; Olszewski WL; Wojewodzka U
Arch Dermatol Res; 2005 Jan; 296(7):286-95. PubMed ID: 15565301
[TBL] [Abstract][Full Text] [Related]
13. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo.
Grøndahl-Hansen J; Lund LR; Ralfkiaer E; Ottevanger V; Danø K
J Invest Dermatol; 1988 Jun; 90(6):790-5. PubMed ID: 3131440
[TBL] [Abstract][Full Text] [Related]
14. Cytokines and growth factors in keratinocytes and sweat glands in chronic venous leg ulcers. An immunohistochemical study.
Tian YW; Stacey MC
Wound Repair Regen; 2003; 11(5):316-25. PubMed ID: 12950634
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts.
Weckroth M; Vaheri A; Myöhänen H; Tukiainen E; Sirén V
Wound Repair Regen; 2001; 9(4):314-22. PubMed ID: 11679140
[TBL] [Abstract][Full Text] [Related]
17. Topically applied recombinant tissue plasminogen activator for the treatment of venous ulcers. Preliminary report.
Falanga V; Carson P; Greenberg A; Hasan A; Nichols E; McPherson J
Dermatol Surg; 1996 Jul; 22(7):643-4. PubMed ID: 8680787
[TBL] [Abstract][Full Text] [Related]
18. Local treatment of venous ulcers with tissue type plasminogen activator containing ointment.
Zeegelaar JE; Verheijen JH; Kerckhaert JA; Jankowski I; Faber WR
Vasa; 1997 May; 26(2):81-4. PubMed ID: 9174382
[TBL] [Abstract][Full Text] [Related]
19. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1.
Hasan A; Murata H; Falabella A; Ochoa S; Zhou L; Badiavas E; Falanga V
J Dermatol Sci; 1997 Nov; 16(1):59-66. PubMed ID: 9438909
[TBL] [Abstract][Full Text] [Related]
20. Sphingosylphosphorylcholine stimulates proliferation and upregulates cell surface-associated plasminogen activator activity in cultured human keratinocytes.
Wakita H; Matsushita K; Nishimura K; Tokura Y; Furukawa F; Takigawa M
J Invest Dermatol; 1998 Mar; 110(3):253-8. PubMed ID: 9506444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
